TZP-102
A phase IIa study demonstrated that TZP-102 reduced abdominal symptoms
without significantly improving gastric emptying in patients with
diabetic gastroparesis, compared with placebo [37]. Subsequently,
phase IIb trials failed to show a significant difference in improving
gastrointestinal mobility between TZP -102 and placebo. No developments
regarding TZP-102 have been updated recently, because Ocera Therapeutics
merged with Tranzyme Pharmaceutical, the maker of TZP-102, in 2013.